Capital World Investors Lowers Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Capital World Investors lessened its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,301,772 shares of the biopharmaceutical company’s stock after selling 132,481 shares during the quarter. Alnylam Pharmaceuticals accounts for about 0.9% of Capital World Investors’ holdings, making the stock its 27th biggest position. Capital World Investors owned approximately 0.12% of Alnylam Pharmaceuticals worth $6,482,389,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Los Angeles Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 50.6% during the 4th quarter. Los Angeles Capital Management LLC now owns 240,052 shares of the biopharmaceutical company’s stock valued at $95,457,000 after acquiring an additional 80,658 shares during the period. Cookson Peirce & Co. Inc. lifted its position in shares of Alnylam Pharmaceuticals by 48.3% during the 4th quarter. Cookson Peirce & Co. Inc. now owns 811 shares of the biopharmaceutical company’s stock valued at $322,000 after acquiring an additional 264 shares during the period. Havemeyer Place LP acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at approximately $118,000. 111 Capital acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at approximately $577,000. Finally, Vestcor Inc lifted its position in shares of Alnylam Pharmaceuticals by 39.8% during the 4th quarter. Vestcor Inc now owns 3,533 shares of the biopharmaceutical company’s stock valued at $1,405,000 after acquiring an additional 1,006 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Down 0.2%

Shares of Alnylam Pharmaceuticals stock opened at $303.05 on Friday. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. Alnylam Pharmaceuticals, Inc. has a 1 year low of $283.10 and a 1 year high of $495.55. The company has a market capitalization of $40.46 billion, a P/E ratio of 82.80 and a beta of 0.29. The business has a 50 day moving average price of $307.66 and a 200 day moving average price of $349.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The firm had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the firm posted ($0.44) EPS. The company’s quarterly revenue was up 96.4% compared to the same quarter last year. Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.47 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ALNY. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Canaccord Genuity Group lifted their price target on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Citigroup began coverage on shares of Alnylam Pharmaceuticals in a research report on Tuesday, May 19th. They set a “buy” rating and a $380.00 price target for the company. Needham & Company LLC reduced their price target on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $463.13.

Insider Activity at Alnylam Pharmaceuticals

In related news, insider Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the transaction, the insider directly owned 9,443 shares in the company, valued at $3,120,156.06. The trade was a 19.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the transaction, the director owned 1,582 shares of the company’s stock, valued at $473,302.76. This represents a 70.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 7,740 shares of company stock valued at $2,420,214 over the last 90 days. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.